| Rus |  |
Eng |  |
A scientific research paper about Two-Dimensional Transition Metal Carbides published in ACS Nano has been selected as recipient of a prestigious award from the American Ceramic Society (ACerS).
Michael Naguib, Olha Mashtalir, Joshua Carle, Volker Presser, Jun Lu, Lars Hultman, Yury Gogotsi, and Michel W. Barsoum, “Two-Dimensional Transition Metal Carbides”, ACS Nano, Vol 6, No. 2, 1322-1331, 2012
ACerS' Ross Coffin Purdy Award recognized the article, which was the first to describe a facile method to produce a large family of two-dimensional layered, early transition metal carbides and nitrides, labeled MXenes. The latter are so-called because they are produced by selective etching of the A-group element — aluminum in this case — from an even larger family of layered solids labeled the MAX phases.
The annual Ross Coffin Purdy Award recognizes researchers "judged to have made the most valuable contribution to ceramic technical literature." The ACerS board unanimously agreed to grant the honor to the Barsoum and Gogotsi team's work.
The award was presented at the ACerS 115th Annual Meeting held in conjunction with MS&T’13 in Montreal, Canada in October 27-31, 2013. The MS&T Conference brings together scientists, engineers, students, suppliers and more to discuss current research and technical applications, and to shape the future of materials science and technology.
RELATED ITEMS:
Roland B. Snow Award 2013 from the American Ceramic Society for the work on The Carbon-Anatase Dog
MXenes potential applications include sensors, wound healing materials, and drug delivery systems. A recent study explored how different synthesis methods affect the safety and performance of MXenes. By comparing etching conditions and intercalation strategies, researchers discovered that fine-tuning the surface chemistry of MXenes plays a crucial role in improving biocompatibility. These results provide practical guidelines for developing safer MXenes and bring the field one step closer to real biomedical applications.
Exellent news, our joint patent application with Drexel University on highly porous MAX phase precursor for MXene synthesis published. Congratulations and thanks to all team involved!
Last Call! Have you submitted your abstract for IEEE NAP-2025 yet? Join us at the International Symposium on "The MXene Frontier: Transformative Nanomaterials Shaping the Future" – the largest MXene-focused conference in Europe this year! Final Submission Deadline: May 15, 2025. Don’t miss this exclusive opportunity to showcase your research and engage with world leaders in the MXene field!
We are excited to announce the publication of latest review article on MXenes in Healthcare. This comprehensive review explores the groundbreaking role of MXenes—an emerging class of 2D materials—in revolutionizing the fields of medical diagnostics and therapeutics. Read the full article here: https://doi.org/10.1039/D4NR04853A.
Congratulations and thank you to our collaborators from TU Wien and CEST for very interesting work and making it published! In this work, an upscalable electrochemical MXene synthesis is presented. Yields of up to 60% electrochemical MXene (EC-MXene) with no byproducts from a single exfoliation cycle are achieved.
Congratulations to all collaborators with this interesting joint work!
Thank you to our collaborators for the amazing joint work recently published in Graphene and 2D Nanomaterials about MXene–silk fibroin composite films aiming to develop materials with tunable electronic and thermal properties
Dr. Oleksiy Gogotsi, director of MRC and Carbon-Ukraine, innovative companies that are among the leaders on the world MXene market, visited 2024 MRS Fall Meeting & Exhibit. together with Dr. Maksym Pogorielov, Head of Advanced Biomaterials and Biophysics Laboratory, University of Latvia.
MRC and Carbon-Ukraine team visited the 3rd International MXene conference held at Drexel University on August 5-8, 2024. Conference brought together the best reserchers and leading experts on MXene field. 
Together with colleagues from the University of Latvia, MRC/Carbone Ukraine, Adam Mickiewicz University, University Clinic Essen, and others, we have developed a novel concept involving the binding of antibodies to MXenes. In our research, we utilized anti-CEACAM1 antibodies to develop targeted photo-thermal therapy for melanoma (in vitro), paving the way for future in vivo studies and clinical trials. For the first time, we demonstrate the feasibility of delivering MXenes specifically targeted to melanoma cells, enabling the effective ablation of cancer cells under near-infrared (NIR) light. This new technique opens up vast potential for the application of MXenes in cancer treatment, diagnostics, drug delivery, and many other medical purposes.
